Skip to main content

Galen Partners completes add-on acquisition for SMP Pharmacy Solutions, a niche-focused, high-touch specialty pharmacy

The addition of Northridge Plaza Pharmacy will enable SMP to meet the growing demand across California’s robust fertility market
STAMFORD, Conn., Oct. 24, 2019 (GLOBE NEWSWIRE) — Galen Partners, a healthcare-focused growth equity investment firm, announced today that its portfolio company, SMP Pharmacy Solutions, has completed an acquisition of Northridge Plaza Pharmacy (NPP), a well-known and trusted entity among fertility clinics in California. The acquisition advances SMP’s strategic expansion plan to enhance its local presence in the West Coast region, where demand for support of the growing fertility market is amongst the highest in the U.S. The financial terms of the transaction have not been disclosed.
“We are excited about the prospect of building upon SMP’s high-touch pharmacy platform in California’s high demand geography,” said Philip Borden, Managing Director at Galen Partners. “Founder & CEO Armando Bardisa and the rest of the SMP team have done a fantastic job of positioning SMP for future growth within fertility and other complex therapeutic areas through the Northridge add-on acquisition.”Armando Bardisa, SMP’s Founder and CEO, stated, “We are excited to extend SMP’s white-glove services to the West Coast. This signifies a major step in our mission to provide industry-leading services throughout the nation.” SMP will provide a host of differentiated services to clinics and patients that include personalized care, superior support, and a robust technology platform. About Galen Partners
Founded in 1990, Galen Partners is a leading healthcare-focused growth equity investment firm. With nearly $1 billion invested over six funds, Galen has invested in and helped to build more than 70 companies since the firm’s inception. Galen continues a tradition of strategic collaboration and partnership with founders and management teams to build healthcare market leaders. Under the direction of the Managing Directors Philip Borden, David Jahns and Zubeen Shroff, Galen seeks to make investments in high-growth healthcare companies with revenues greater than $10 million and EBITDA between $0 and $9 million. SMP represents an investment out of Galen Fund VI.
For more information, please visit www.galen.com.About SMP Pharmacy Solutions
SMP Pharmacy Solutions is a leading high growth specialty pharmacy that provides treatments for a variety of complex disease states. Since 2003, management has grown SMP from a local retail pharmacy to a nationwide specialty pharmacy with licenses in 50 states and strategic partnerships with leading manufacturers and MSOs. SMP differentiates itself from other specialty pharmacies by its industry-leading service, combining customizable patient management and pharmacy programs with access to in-demand therapeutics. SMP has established a nationwide reputation with patients, payors, providers, and manufacturers for delivering true healthcare value to all constituents. SMP has developed specific therapeutic expertise throughout a wide array of disease states, with a particular focus on fertility. 
For more information, please visit www.smppharmacy.comStacey Bauer
Office: (203) 653-6473
sbauer@galen.com 

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.